2 April 2026 at 08:02:22
Global CRO and Clinical Trial Markets
Projected for Robust Growth Through 2030
According to Fierce Biotech the global CRO market is poised for significant expansion, projected to reach nearly $63 billion by 2030 with an average annual growth rate $7.4 billion by 2030.
Key Market Drivers
Outsourcing and R&D Investment
Growth in both markets is being driven by increased outsourcing and rising R&D expenditure across the biopharmaceutical sector. Companies are increasingly leveraging external expertise and turning to CROs to control costs and accelerate drug development timelines.
Therapeutic Focus
Oncology dominates both markets, representing 30.66% of the CRO market and 35.1% of the clinical trial market in 2024. This reflects both the volume of cancer trials and the complexity of modern oncology studies.
Geographic Expansion: Asia-Pacific Leads
The Asia-Pacific region is experiencing the most dramatic growth, already commanding 46.4% of the global CRO market share in 2024. This surge is driven by increased local CRO activity and growing trial outsourcing to the region.
China's rise has been particularly striking, the country's share of global oncology trial starts jumped from 8% in 2013 to 29% in 2023. Meanwhile, North America, historically the largest market at over 35% share in 2024, is declining relatively as investment and trial activity shift eastward. Europe's market share has also contracted during this period.
India, Southeast Asia, and emerging markets in Latin America and Africa are also attracting trials through lower operational costs and improved regulatory infrastructure.
Industry Outlook
The clinical trials sector faces near-term headwinds including rising costs and regulatory uncertainties in 2025, yet the long-term trajectory remains positive. Site management organizations are gaining adoption, with usage among phase 3 trials rising from 15% in 2021 to 21% in 2023. Additionally, digital tools, AI, and obesity-related trials are expected to proliferate.